H.C. Wainwright starts vTv Therapeutics with 'buy' as diabetes drug study set to resume

vTv Therapeutics

09/04/2025 12:59

** Drug developer vTv Therapeutics' shares VTVT.O rise 3.2% to $16.3 premarket

** Brokerage H.C. Wainwright starts coverage with "buy" rating, sets PT at $36

 ** The new price target is more than double the stock's last close

** Brokerage says a late-stage study of "underappreciated" diabetes therapy is set to resume in Q2 after the FDA lifted the clinical hold in March 2025

** Company is testing cadisegliatin, an oral adjunctive therapy to insulin for treatment of type 1 diabetes

** Brokerage believes overhang has been lifted from VTVT's shares and company can now enroll the patients in the late-stage study

** Up to last close, stock up 14.4% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))